Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents.
about
Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plansAttitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research ResultsAlzheimer Disease and Its Growing Epidemic: Risk Factors, Biomarkers, and the Urgent Need for Therapeutics.Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness researchHow much diagnostic safety can we afford, and how should we decide? A health economics perspective.Return of genomic results to research participants: the floor, the ceiling, and the choices in between.Public beliefs and knowledge about risk and protective factors for Alzheimer's diseaseEmerging issues in public health genomics.Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps.Willingness to pay for genetic testing for inherited retinal disease.Public perceptions of presymptomatic testing for Alzheimer diseaseDirect-to-consumer genomics on the scales of autonomy.Concepts of 'personalization' in personalized medicine: implications for economic evaluation.Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utilityValuations of genetic test information for treatable conditions: the case of colorectal cancer screening.Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues.Using willingness-to-pay to establish patient preferences for cancer testing in primary care.Hepatitis C screening: getting it right."Is it really worth it to get tested?": primary care patients' impressions of predictive SNP testing for colon cancer.Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trialsGenetic susceptibility testing for neurodegenerative diseases: ethical and practice issues.A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases.Desire for predictive testing for Alzheimer's disease and impact on advance care planning: a cross-sectional study.Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease.The economic considerations and implications of the stratification of future oncology therapeutics.Personal utility in genomic testing: a systematic literature review.Attitudes to Alzheimer's disease testing of Australian general practice patients: a cross-sectional questionnaire-based study.Valuing Meta-Health Effects for Use in Economic Evaluations to Inform Reimbursement Decisions: A Review of the Evidence.Socioeconomic disparities, financial toxicity, and opportunities for enhanced system efficiencies for patients with cancer.Does the Public Prefer Health Gain for Cancer Patients? A Systematic Review of Public Views on Cancer and its Characteristics.Why do we pay for information that we won't use? A cognitive-based explanation for genetic information seeking.The price of whole-genome sequencing may be decreasing, but who will be sequenced?Estimating Preferences for Complex Health Technologies: Lessons Learned and Implications for Personalized Medicine.Effect of co-payment on behavioral response to consumer genomic testing.Awareness and attitude of the public toward personalized medicine in Korea.Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir.Consumer genetics and addiction susceptibility testing-just what the consumer ordered.Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of Québec (Canada).Primary Care Patients’ Views, Attitudes, and Decision-Making Factors Regarding Direct-to-Consumer Personal Genome Testing: Results From a Qualitative StudyPopulation Health Solutions for Assessing Cognitive Impairment in Geriatric Patients
P2860
Q26801647-2C23F8CD-9E49-4A49-BF68-B7B21ADB1A9CQ27345258-86BA4518-682C-4527-B5A4-F8325E3C6C43Q30244736-6FECD959-B236-423C-B5AE-A0EB174A814BQ30419845-8F3CB469-25A2-4E95-82DC-D792ECEF60C4Q30547637-B88ECA18-D4BA-4EA5-8E7C-99BEEAD86527Q34000877-1042900F-0255-494D-A02C-777169E0799BQ34177996-06A8D65E-0EA1-4211-A739-902B95320BBDQ34496940-88B6AF10-7402-4F68-B517-61E074F72DFAQ34552387-041C1084-2E0D-4828-B685-B90E14500651Q35079939-46C3FE7F-18E7-47E4-BC7F-55ED58DF83A3Q35206422-13078663-AA8D-48D4-AC2F-3CAADD14EFF6Q35351251-7AC45BDB-63D0-4DA6-8CB9-F82CE0DC620DQ35575935-79BFBC23-34C5-45BD-9743-017EA6741CDEQ35621042-1491840B-5ED8-47E9-9F0B-F2D8CFE17E87Q35822142-671F633D-3A0D-4BAB-8A8B-78A690C8AF1CQ35838385-F2DE5024-80AB-4D3A-A08D-8C06511AD577Q36098245-4B75A80C-135A-470A-99C5-33D459DC8B8CQ36575211-903142D7-A593-4F18-8A34-39D0AD3A38BFQ36595655-0928CF9E-3F4B-42E8-B39E-86C4416ACE68Q36638757-3D63A93D-818F-484B-BDAA-4D0466A12691Q37170455-161EF5B0-3CAF-4079-B500-69AE1AF88AADQ37323166-E80DE5E4-E58E-4BC8-AA86-FEC42CBCE311Q37498154-AEC3E046-CDA1-4864-8447-F2D570B60FF4Q37690501-8282EC7D-6910-4A4B-9E4D-1A35158BB7C5Q38211622-91CC72C1-5FA3-481A-BC0F-4B2022B42E5CQ38745230-05262B1D-6B60-4371-945D-BBA6B76926A7Q38975863-94ED7ED7-6232-4586-8C3E-D4531221C55EQ39011868-311904EB-AB07-400C-ACAC-006A67B068B8Q39096107-4DACD432-1358-4CDC-BF15-F2CDC214077EQ39271791-F2D7FB86-7210-4ABD-9B82-05B39229793CQ42449838-84508B17-6750-4F4A-A8BB-E16133D5787CQ46829097-AB8D28FB-04B4-48A9-B0AC-76F54ED707E2Q47363206-18B6C120-66F5-4C62-BD64-640D01460511Q49551505-3A664B4C-9E6E-46A5-8A28-F39E30C34C45Q49924790-2CED7BC1-A039-46DF-80F6-733AF0C08A04Q50981551-B1AEF298-A4B9-499C-A47D-081701495C17Q52301797-E5DD7F37-F50F-42D1-BBFB-4B92750EC4BDQ52682549-D2EC37CF-949A-4859-8AA8-5FD4FEEDF1C8Q58106631-A538AA04-67D5-4EC9-9B03-A609FBE73858Q58556716-7BB25E6D-6552-487B-8C25-A989AD57A1CF
P2860
Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Willingness-to-pay for predict ...... ons: a survey of US residents.
@en
Willingness-to-pay for predict ...... ons: a survey of US residents.
@nl
type
label
Willingness-to-pay for predict ...... ons: a survey of US residents.
@en
Willingness-to-pay for predict ...... ons: a survey of US residents.
@nl
prefLabel
Willingness-to-pay for predict ...... ons: a survey of US residents.
@en
Willingness-to-pay for predict ...... ons: a survey of US residents.
@nl
P2093
P2860
P356
P1433
P1476
Willingness-to-pay for predict ...... ons: a survey of US residents.
@en
P2093
Chihui Fang
David M Kent
Hannah R Auerbach
Peter J Neumann
Thomas W Concannon
P2860
P304
P356
10.1002/HEC.1704
P407
P577
2010-12-28T00:00:00Z